Our findings—the distinction between SCLC neuroendocrine phenotypes based on cfDNA accessibility of binding sites of TFs such as REST, ASCL1, and NEUROD1—could allow for noninvasive characterization and treatment for patients. The gene discussed is ASCL1; the disease is small cell lung carcinoma.